Details of the Drug

General Information of Drug (ID: DMZ0F65)

• Drug Name: Contezolid
• Synonyms: MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796

Indication

Disease Entry	ICD 11	Status	REF
MRSA infection	1D01.0Y	Phase 2	[1]
Skin infection	1F28-1G0Z	Phase 2	[2]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 408.3
  Logarithm of the Partition Coefficient (xlogp); 2
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 10
• Chemical Identifiers:
  Formula: C18H15F3N4O4
  IUPAC Name: (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one
  Canonical SMILES: C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
  InChI: InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
  InChIKey: SULYVXZZUMRQAX-NSHDSACASA-N
• Cross-matching ID:
  PubChem CID: 25184541
  CAS Number: 1112968-42-9
  DrugBank ID: DB12796
  TTD ID: D0I2GS
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein synthesis (hPRO synth)	TTLIZBJ	NOUNIPROTAC	Inhibitor	[2]

References

• [1] MICURX PHARMACEUTICALS COMPLETES PHASE 1 TRIAL FOR MRX-I, A NEXT-GENERATION ANTIBIOTIC. Micurx pharmaceuticals.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)